Operate a comprehensive online platform providing information about cannabis products and strains. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (-1% a year). Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 3.3× for every dollar of annual revenue.
No analyst target is on record for this company.
An investor who bought at the very peak is down 84% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $34.6M a year. A small number, but proof the product has real buyers.
A loss of $5.7M against $34.6M in annual sales. And on top of that, sales fell from the year before.
Over the last 12 months, executives reported 48 sells against just 3 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.